HPS Pharmacies wish to advise that Seqirus is experiencing a supply interruption for Palexia® IR as follows:
Palexia® IR 50mg Tablets
Tapentadol (as hydrochloride) 50 mg
ARTG 165310
This supply interruption is due to a delay in delivery from the manufacturer. Normal supplies are expected to resume by late January to early February 2026. Consult prescribers for suitable alternative opioids during this shortage.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Seqirus on 1800 008 275, or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates